IP Library Patent Application 16903132
Patent Application
App. No. 16/903,132

AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/903,132
Abstract

The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.

Claims (8)

1 .- 10 . (canceled)

11 . A method of treating a chronic pulmonary infection due to Pseudomonas aeruginosa in a subject with cystic fibrosis in need thereof, the method comprising administering to the lungs of the subject with cystic fibrosis about 240 mg of an aerosol of a solution comprising about 100 mg/ml of levofloxacin and about 200 mM of magnesium chloride; wherein the solution has a pH from about 5 to about 7 and an osmolality from about 350 mOsmol/kg to about 400 mOsmol/kg, to treat the chronic pulmonary infection due to Pseudomonas aeruginosa.

12 . A method of treating a Pseudomonas aeruginosa pulmonary infection in a subject in need thereof, the method comprising administering to the lungs of the subject an aerosol of a solution comprising from about 90 mg/ml to about 110 mg/ml of levofloxacin and from about 190 mM to about 210 mM of a magnesium cation to treat the Pseudomonas aeruginosa pulmonary infection.

13 . The method of claim 12 , wherein the subject has cystic fibrosis.

14 . The method of claim 12 , wherein the solution comprises about 100 mg/ml of levofloxacin and about 200 mM of the magnesium cation; wherein the solution has a pH from about 5 to about 7 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg; and wherein from about 200 mg to about 280 mg of levofloxacin is administered to the subject.

15 . The method of claim 14 wherein from about 230 mg to about 250 mg of levofloxacin is administered to the subject.

16 . The method of claim 14 wherein the solution has a pH from about 6.0 to about 6.5 and an osmolality from about 350 mOsmol/kg to about 400 mOsmol/kg.

17 . The method of claim 14 , wherein the magnesium cation is in the form of magnesium chloride.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS U.S. HOLDING LLC (FKA HORIZON ORPHAN LLC); HZNP LIMITED; HORIZON THERAPEUTICS U.S. HOLDING LLC (SUCCESSOR IN INTEREST TO HORIZON THERAPEUTICS, LLC)
Reel/Frame 065154/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2021
From: GRIFFITH, DAVID C; DUDLEY, MICHAEL N; SURBER, MARK W; BOSTIAN, KEITH A; RODNY, OLGA
To: MPEX PHARMACEUTICALS, INC.
Reel/Frame 056383/0051 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2021
From: MPEX PHARMACEUTICALS, INC.
To: TRIPEX PHARMACEUTICALS, LLC
Reel/Frame 056383/0920 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2021
From: TRIPEX PHARMACEUTICALS, LLC
To: RAPTOR PHARMACEUTICALS INC.
Reel/Frame 056422/0235 →
CHANGE OF NAME Recorded May 28, 2021
From: RAPTOR PHARMACEUTICALS INC.
To: HORIZON ORPHAN LLC
Reel/Frame 056424/0102 →
SECURITY AGREEMENT Recorded Aug 17, 2020
From: HORIZON ORPHAN LLC; HORIZON THERAPEUTICS, LLC; HZNP LIMITED
To: CITIBANK, N.A.
Reel/Frame 053515/0273 →